Zepbound Canada: Cost, Coverage, Dosing and Comparisons

Updated September 11, 2026

Zepbound (tirzepatide) is available in Canada by prescription for chronic weight management in eligible adults. In June 2026, Health Canada also authorized Zepbound for moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity, correcting an important change since this article was first published.

This guide explains who may meet the Canadian label criteria, how Zepbound differs from Mounjaro, Ozempic and Wegovy, what current pricing and coverage can look like, and the dosing and safety points to discuss with a physician. Zepbound is not appropriate for everyone, and meeting label criteria does not guarantee a prescription or insurance coverage.

What Is Zepbound?

Zepbound is a once-weekly prescription injection manufactured by Eli Lilly. Its active ingredient is tirzepatide, a dual GIP and GLP-1 receptor agonist. Mounjaro also contains tirzepatide, but the two brands have different Health Canada indications and product information.

For chronic weight management, the Canadian label covers adults with an initial BMI of 30 kg/m² or higher, or 27 to under 30 kg/m² with at least one weight-related condition such as hypertension, dyslipidemia, prediabetes, type 2 diabetes, OSA or cardiovascular disease. It is used with a reduced-calorie diet and increased physical activity. A physician still needs to assess medical history, medicines, contraindications and treatment goals.

How Does Zepbound Work for Weight Loss?

Zepbound mimics GLP-1 and GIP, which are two incretin hormones released by the intestine after meals. These hormones work on overlapping but distinct parts of the body’s appetite and energy regulation system. 

Activating the GLP-1 receptor is known to:

• Slow gastric emptying
• Reduce hunger signals in the brain
• Enhance insulin secretion

The added GIP receptor activation from Zepbound appears to amplify these effects, and may also influence how the body stores and uses fat.

In practice, Zepbound weight loss occurs in a similar way to other GLP-1 medications. Food stays in the stomach longer after meals, hunger between meals is reduced, and many people report a noticeable drop in the persistent background thoughts about food.

How Much Weight Can You Lose on Zepbound?

In clinical trials, adults on the highest dose of Zepbound lost an average of roughly 21% of their body weight over 72 weeks. This is the largest average weight loss reported for any prescription medication currently approved in Canada for chronic weight management.

Below is a brief summary of the main research trials done with Zepbound and the weight loss results achieved. 

SURMOUNT-1 Trial Results

The main evidence for Zepbound comes from SURMOUNT-1, a phase 3 randomized trial of 2,539 adults with obesity or overweight (without type 2 diabetes), treated with tirzepatide (the active ingredient of Zepbound). 

Over 72 weeks, average weight loss was:

• 5 mg dose: 15.0% of body weight
• 10 mg dose: 19.5% of body weight
• 15 mg dose: 20.9% of body weight
• Placebo: 3.1% of body weight

About 91% of participants on the 15 mg Zepbound dose lost at least 5% of their body weight, and more than half lost 20% or more.

Long-Term Results

A three-year follow-up analysis of patients enrolled in the SURMOUNT trial confirmed the weight loss from Zepbound was sustained over 176 weeks, with an average weight loss of 19.7% after three years on the 15 mg dose. This analysis also found that treatment significantly reduced the rate of progression from prediabetes to type 2 diabetes.

What Happens If You Stop Taking Zepbound?

As with all GLP-1-based medications, the results from Zepbound largely depend on staying on the medication. Observational and trial data suggest most of the weight is regained if treatment is stopped. This is why Zepbound (like Wegovy, Ozempic, and Mounjaro) is considered a long-term therapy.

Is Zepbound Available in Canada?

Health Canada approved Zepbound on May 13, 2025, and Eli Lilly launched the medication at Canadian pharmacies on July 9, 2025. It is a prescription-only medication, which means patients need to consult with a licensed Canadian healthcare provider to determine whether it’s an appropriate treatment option for them.

In Canada, Zepbound is sold exclusively as the KwikPen — a multi-dose prefilled pen containing four weekly doses. This is a different format from the single-dose auto-injector pens Zepbound launched with in the United States.

Zepbound vs Mounjaro

Zepbound and Mounjaro contain the same active ingredient, tirzepatide, and are available in comparable strengths. They are not interchangeable labels: Zepbound is authorized for chronic weight management and, as of 2026, moderate-to-severe OSA in adults with obesity; Mounjaro is authorized for type 2 diabetes.

The shared ingredient does not mean every person will have an identical treatment plan, response, coverage decision or product experience. A physician chooses a product and dose based on the approved indication, the person’s health, other medicines, availability and coverage.

What About Off-Label Mounjaro?

Off-label prescribing is legal in Canada when a qualified prescriber decides it is clinically appropriate, but it is not guaranteed. Zepbound now provides an on-label tirzepatide option for eligible weight-management patients. Public and private coverage is plan-specific: the brand name, indication, prior-authorization rules and benefit maximums can all affect reimbursement. Lilly’s support or savings programs can reduce cost for some eligible patients, but they do not guarantee insurance coverage.

Zepbound vs Ozempic: Are They the Same?

Zepbound (tirzepatide) and Ozempic (semaglutide) are different molecules made by different manufacturers. They are often grouped together in conversation as “GLP-1s,” but this comparison is imprecise.

While there is some overlap between how Zepbound and Ozempic work, there are several important differences to be aware of, including:

• Active ingredient: Zepbound contains tirzepatide, while Ozempic contains semaglutide — two distinct molecules.
• Mechanism: Zepbound is a dual agonist that activates both GLP-1 and GIP receptors. Ozempic is a GLP-1 receptor agonist only.
• Manufacturer: Zepbound is made by Eli Lilly; Ozempic is made by Novo Nordisk.
• Canadian indication: Zepbound is approved for chronic weight management. Ozempic is approved only for type 2 diabetes, so any prescription for weight loss is off-label — the on-label semaglutide option for weight management in Canada is Wegovy.
• Weight loss outcomes: Average weight loss on tirzepatide has been greater than on semaglutide in head-to-head trial data.

In short, Zepbound and Ozempic are part of the same broader drug class, but they are not interchangeable. The medications have different molecules, different mechanisms, and different approved uses in Canada.

Zepbound vs Wegovy

The most relevant head-to-head comparison for Canadians considering Zepbound is against Wegovy, the branded version of semaglutide approved for weight management. 

Both are once-weekly GLP-1-based injectables approved by Health Canada for weight management. However, there are some important differences between the medications that patients should be aware of.

We cover the main differences between Zepbound and Wegovy below. But as always, you should speak with a doctor to get advice based on your personal situation before deciding which one might be right for you.

SURMOUNT-5: The Head-to-Head Trial

The SURMOUNT-5 trial compared Zepbound and Wegovy directly over 72 weeks in 751 adults with obesity or overweight, without diabetes. 

Here are the key findings:

• Average weight loss: 20.2% on Zepbound vs 13.7% on Wegovy (roughly 47% more weight loss from Zepbound).
• Participants who lost 15% of body weight or more: 64.6% on Zepbound vs 40.1% on Wegovy.
• Participants who lost 25% of body weight or more: 31.6% on Zepbound vs 16.1% on Wegovy.
• Discontinuation due to side effects: 2.7% on Zepbound vs 5.6% on Wegovy.

In this open-label trial of adults with obesity without diabetes, tirzepatide produced greater average weight loss than semaglutide. That result does not establish which medicine is best for every patient.

Where Wegovy Still Has an Edge

Greater weight loss does not automatically make Zepbound the right choice for every person. 

Here are a few things that work in Wegovy’s favour:

• Cardiovascular outcome data: The SELECT trial demonstrated that Wegovy reduced the risk of major adverse cardiovascular events in adults with obesity and established heart disease. Zepbound does not yet have equivalent outcome data, though trials are ongoing.
• Longer track record in Canada: Wegovy has been prescribed in Canada for longer than Zepbound, meaning both doctors and patients have more real-world familiarity with how it performs outside a clinical trial setting.

Choosing Between Zepbound and Wegovy

There is no universally correct answer about whether Wegovy vs Zepbound is the best choice. 

The right fit always depends on an individual’s medical history, weight loss goals, susceptibility to side effects, cost, insurance coverage, and whether cardiovascular risk reduction is a specific treatment priority. In all cases, this decision should be made with a licensed healthcare provider who can review your full medical history and personal background.

Is Zepbound Approved for Sleep Apnea in Canada?

Yes. Health Canada authorized Zepbound in June 2026 for moderate-to-severe obstructive sleep apnea in adults with obesity. This is a separate approved use from the chronic-weight-management indication. Eligibility and ongoing OSA care require a clinical assessment; Zepbound should not be treated as an automatic replacement for CPAP, an oral appliance or another OSA treatment.

In the SURMOUNT-OSA trials, adults with obesity and moderate-to-severe OSA had larger reductions in apnea-hypopnea events with tirzepatide than with placebo over 52 weeks, whether or not participants were using positive airway pressure at baseline. Results were averages from selected trial participants and do not predict an individual’s response.

How Much Does Zepbound Cost in Canada?

There is no single Canadian cash price. Pharmacy price, dispensing fees, province, insurance and savings-program eligibility can change the amount paid. Eli Lilly Canada currently says eligible patients may start Zepbound for as low as $300 per month with its Savings Card; exclusions and exceptions apply, dispensing fees are not included, and the actual price can vary.

Coverage also varies. Some private plans exclude weight-management medicines, while others require prior authorization or apply clinical criteria, copays and annual limits. Public-plan status and OSA coverage can differ by province and indication. Check the current formulary or benefits booklet and ask the insurer or pharmacy what documentation is required before relying on an estimate.

A lower advertised or card-assisted price is not the same as guaranteed reimbursement. Ask the pharmacy for the total 28-day cost, including fees, and confirm whether a savings card can be combined with your plan.

Zepbound Dosing

The Canadian product monograph uses gradual dose escalation to improve gastrointestinal tolerability. A physician may delay an increase or choose a lower maintenance dose based on response and side effects.

The labelled schedule is:

• Weeks 1–4: 2.5 mg once weekly for treatment initiation; it is not a maintenance dose
• After 4 weeks: increase to 5 mg once weekly
• If needed and tolerated: increase in 2.5 mg steps after at least 4 weeks on the current dose
• Maintenance doses: 5 mg, 10 mg or 15 mg once weekly
• Maximum: 15 mg once weekly

For a missed dose, the Canadian monograph says to take it as soon as possible within four days (96 hours). If more than four days have passed, skip it and take the next dose on the regular day. Never double a dose. The KwikPen contains four weekly doses; follow the supplied Instructions for Use and the training provided by a healthcare professional.

Zepbound Side Effects

As with other GLP-1 and GLP-1/GIP agonists, side effects of Zepbound are mostly gastrointestinal. 

The most commonly reported include:

• Nausea
• Diarrhea
• Constipation
• Vomiting
• Abdominal pain
• Decreased appetite
• Fatigue
• Injection-site reactions

Gastrointestinal side effects were often mild to moderate in trials, but severe reactions can occur. Contact a healthcare professional if symptoms are persistent, worsening or make it difficult to stay hydrated. 

In SURMOUNT-1, discontinuation due to adverse events on the highest dose was around 6%, and the pattern of side effects was similar to what’s seen with other GLP-1-based weight loss treatments.

Tips for Managing Zepbound Side Effects

To reduce the likelihood of gastrointestinal discomfort from Zepbound, consider:

• Eating smaller and more frequent meals rather than large ones
• Avoiding greasy, fried, or heavily spiced foods (especially during dose increases)
• Staying well hydrated
• Eating slowly until you feel satisfied rather than full

These are the same strategies recommended for patients on Ozempic, Wegovy, and Mounjaro.

Serious Risks and Who Should Not Take Zepbound

The Canadian monograph has a Serious Warnings and Precautions box about thyroid C-cell tumours seen in rats; it is unknown whether Zepbound causes these tumours in humans. Zepbound is contraindicated for anyone with a personal or family history of medullary thyroid carcinoma (MTC), Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), hypersensitivity to tirzepatide or an ingredient, and during pregnancy or breastfeeding.

Important risks and precautions include pancreatitis, acute gallbladder disease, dehydration-related kidney injury, severe gastrointestinal reactions, serious allergic reactions, diabetic-retinopathy complications in some people with type 2 diabetes, hypoglycemia when used with insulin or a sulfonylurea, and aspiration risk during general anesthesia or deep sedation. Zepbound has not been studied in severe gastrointestinal disease, including severe gastroparesis, and is not recommended in those patients. A prior history of pancreatitis calls for caution rather than an automatic blanket contraindication.

Do not combine Zepbound with Mounjaro, another tirzepatide product or a GLP-1 receptor agonist. Tell surgical or anesthesia teams that you use it. Because tirzepatide can affect oral hormonal contraceptive absorption, the Canadian monograph advises switching to a non-oral method or adding a barrier method for four weeks after starting and for four weeks after each dose increase. Seek urgent care for symptoms of a serious allergic reaction or severe, persistent abdominal pain.

Frequently Asked Questions About Zepbound

Is Zepbound available in Canada?

Yes. Zepbound is available by prescription in Canada in a multi-dose KwikPen containing four weekly doses. Pharmacy stock can vary.

Who may qualify for Zepbound for weight management?

The Canadian label covers adults with an initial BMI of at least 30 kg/m², or 27 to under 30 kg/m² with at least one weight-related condition. Meeting those thresholds does not guarantee that Zepbound is appropriate or that it will be prescribed.

Is Zepbound approved for sleep apnea in Canada?

Yes. Since June 2026, it has been authorized for moderate-to-severe obstructive sleep apnea in adults with obesity. A physician should assess whether it fits the person’s OSA treatment plan.

How much is Zepbound in Canada without insurance?

Prices vary by pharmacy and fees. Lilly Canada currently advertises that eligible patients may start for as low as $300 per month with a Savings Card, subject to exclusions. Ask the pharmacy for the total 28-day cash price and confirm card eligibility.

Does insurance cover Zepbound in Canada?

Coverage is plan-, province- and indication-specific. Prior authorization, clinical criteria, copays and benefit limits may apply. Confirm directly with the insurer or public formulary.

Is Zepbound the same as Ozempic?

No. Zepbound contains tirzepatide and activates GIP and GLP-1 receptors. Ozempic contains semaglutide and is a GLP-1 receptor agonist. Their Health Canada indications also differ.

Is Zepbound the same as Mounjaro?

They contain the same active ingredient, tirzepatide, but are different brands with different approved indications and product information. They should not be used together.

How much weight can you lose on Zepbound?

In SURMOUNT-1, adults without type 2 diabetes assigned to 15 mg tirzepatide lost an average of 20.9% of body weight over 72 weeks. Individual results vary, and trial averages are not a guarantee.

Zepbound Canada: Final Thoughts

Zepbound is an on-label tirzepatide option in Canada for eligible adults seeking chronic weight management and, since 2026, for certain adults with obesity and moderate-to-severe OSA. The most suitable option depends on medical history, other medicines, treatment goals, side effects, availability and verified coverage—not on average trial results alone.

Walk In connects eligible patients in selected Metro Vancouver communities with physicians by phone or video. The physician will assess whether a weight-management medicine is clinically appropriate; an appointment does not guarantee a prescription, coverage or a particular outcome.

Speak With a Physician About Weight-Management Options